The LightPath® Breast Cancer Study

A Multi-centre Clinical Study to Evaluate the LightPath® Imaging System in Wide Local Excision (WLE) for Breast Cancer

This study is a prospective, single arm, multi-centre study to evaluate the intra-operative use of the LightPath® Imaging System for the assessment of tumour margin status compared to hospital standard of care histopathology in wide local excision (WLE) for breast cancer

The intraoperative 18F-fluorodeoxyglucose (18F-FDG) LightPath® Images will be used to inform the surgeons about detectable residual cancer, in an attempt to achieve better guided cancer surgery and complete tumour excision with clear WLE resection margins.

Study sites will use the local criteria considered standard of care to guide decisions to act on positive margins.

In the LightPath® arm the resection margin status of the WLE specimen, cavity shavings (if any) and the metastatic status of axillary (sentinel) lymph nodes as measured with the LightPath® Imaging System will be compared with histopathology results.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer
• Intervention / Treatment: Device: LightPath® Imaging System.

Detailed Description

Female subjects with a diagnosis of invasive breast cancer scheduled to have wide local excision (WLE) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) will be screened and receive 18F-FDG plus LightPath® Image. Subjects will have standard of care WLE. Extra cavity shaving due to positive 18F-FDG LightPath® Images is at the discretion of the surgeon.

Subjects will receive an intravenous injection of up to 5 MBq/kg, to a maximum 300 MegaBecquerel (MBq) of 18F-FDG prior to surgery.

Following resection, the WLE specimen will be examined using the LightPath® Imaging System. If the surgeons detect a positive signal they may perform cavity shavings of the resection cavity area corresponding to the positive signal area (up to a maximum thickness of 10mm).

Axillary SLNB will be performed according to local practice. At sites where 99mTc is used: In the 18F-FDG + LightPath® a higher dose of up to 150 MBq technetium-99m (99mTc) nanocolloid is necessary to avoid 18F-FDG masking the signal from 99mTc. Blue dye will be used according to local practice at sites where it is considered standard of care.

Sentinel lymph nodes (SLNs) will be examined using the LightPath® Imaging System. Where clinically indicated, ALND will be performed as per standard of care. At the time this protocol was finalised, LightPath® data involved lymph nodes sufficient to support recommendations were not available. For this reason, LightPath® Image results will not be used to direct ALND.

All LightPath® Images will be performed between 60 and 180 minutes post injection of 18F-FDG.

The WLE specimen, cavity shavings (where performed) and SLNs (where performed) will then undergo standard of care histopathological analysis. Lymph nodes will also be examined according to standard of care histopathological analysis. The results of the histopathological analysis will then be correlated with the LightPath® Images.

All staff in the operating room will wear badge dosimeters. Staff handling surgical specimens in theatre will also wear ring dosimeters. Histopathology analyses should be delayed to allow for radioactive decay of tissue samples to suitably low levels.

Subjects will be evaluated at screening and enrolment into the study. Data will be collected until the decision by the study site's MDT to recommend re-excision or mastectomy because of a positive margin on histopathological analysis (approx. 1-6 weeks post surgery)

• Study Type: Interventional
• Enrollment (Anticipated): 170
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Qamar B Akbar; Phone Number: +44 (0) 1494 917 697; Email: qamar.akbar@lightpointmedical.com

Study Locations

• Poland
  • Gliwice, Poland, 44-101
    • Recruiting
    • Klinika Chirurgii Onkologicznej i Rekonstrukcyjnej Centrum Onkologii- Instytut oddział w Gliwicach, ul. Wybrzeże Armii Krajowej 15,
    • Contact: Maria Turska-d'Amico, MD
  • Kraków, Poland, 31-501
    • Recruiting
    • Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Endokrynologii, ul. Mikołaja Kopernika 17,
    • Contact: Anna Sowa-Staszczak, MD, PhD
  • Warszawa, Poland, 02-781
    • Recruiting
    • Centrum Onkologii - Instytut, im Marii Skłodowskiej-Curie, Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej ul. Roetgena 5
    • Contact: Prof. Zbigniew Nowecki, MD, PhD
• United Kingdom
  • Liverpool, United Kingdom, L7 8XP
    • Terminated
    • Royal Liverpool Hospital
  • Llandough, United Kingdom, CF64 2XX
    • Active, not recruiting
    • Cardiff Breast Centre, LLandough Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Subjects who have signed an informed consent form prior to any study related activity
• Subjects who are able to give voluntary, written informed consent to participate in this study.
• Subjects who are able to understand this study and are willing to complete all the study assessments
• Female participants ≥18 years of age with a diagnosis of invasive breast cancer
• Subjects who have disease in one quadrant of the breast, not including the nipple
• Subjects scheduled for WLE for breast cancer +/- SLNB or ALND.
• Females of childbearing age must have a negative pregnancy test (by Beta human chorionic gonadotropin (HCG) qualitative analysis), or must have had a history of a surgical sterilisation, or must give history of no menses in the past twelve months

Exclusion Criteria:

• Subjects with pure DCIS or with pleomorphic LCIS
• Subjects who have had surgery in the ipsilateral breast in the past 12 months
• Subjects who have had radiotherapy in the ipsilateral breast
• Subjects who have had neoadjuvant systemic therapy
• Subjects who have had systemic chemotherapy in the past two years
• Subjects with a non-palpable lesion scheduled to have radio guided occult lesion localisation (ROLL)
• Subjects who have known hypersensitivity to 18F-FDG
• Subjects who are pregnant or lactating
• Subjects who have an existing medical condition that would compromise their participation in the study
• Subjects who have participated in a clinical study in the last 2 months
• Subjects with a current or active history of other known cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment arm; Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.	Device: LightPath® Imaging System.; Intra-operative use of the LightPath® Imaging System.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diagnostic performance of the LightPath® Imaging System	The diagnostic performance of tumour margin assessment with the LightPath® Imaging System compared to hospital histopathology.	Initial surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The recommendation by the study site's multidisciplinary team (MDT) to re-operate at the index location (breast) within 1 to 6 weeks post-initial surgery according to local practice.	MDT recommendation for the subject to undergo re-excision or mastectomy because of a positive margin on histopathological analysis.	1-6 weeks post initial surgery
Rate of re-operation at the index location	The number of subjects undergoing re-operation at the index location because of a positive margin on histopathological analysis, compared to published data on re-operation rates.	1 to 6 weeks post initial surgery
Volume of tissue excised	Weight (g) of all fresh pieces of tissue removed	Initial surgery
Radiation dosimetry	Dosimetry readings will be summarised by staff member and procedure	Initial surgery
Safety - adverse events (related to breast surgery)	Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether r not related to the device	Initial surgery

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agreement between LightPath® Image for lymph nodes status and histology	Proportion of lymph nodes that agree metastatic status	Initial surgery
Biomarkers ER/PR/HER2 status	ER/PR/HER2 will each be defined as positive or negative in accordance with local practice	Screening

Collaborators and Investigators

• Sponsor: Lightpoint Medical Limited
• Collaborators: European Commission
• Investigators: Study Director: Qamar B Akbar, MSc, Clinical Project Manager

Publications and helpful links

General Publications

• Jurrius PAGT, Grootendorst MR, Krotewicz M, Cariati M, Kothari A, Patani N, Karcz P, Nagadowska M, Vyas KN, Purushotham A, Turska-d'Amico M. Intraoperative [(18)F]FDG flexible autoradiography for tumour margin assessment in breast-conserving surgery: a first-in-human multicentre feasibility study. EJNMMI Res. 2021 Mar 18;11(1):28. doi: 10.1186/s13550-021-00759-w.

Helpful Links

• Company website with description of the technology and Conformité Européenne (CE) marked medical device
• ISRCTN17778965

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2017
• Primary Completion (Anticipated): November 1, 2018
• Study Completion (Anticipated): December 1, 2018

Study Registration Dates

• First Submitted: January 25, 2016
• First Submitted That Met QC Criteria: January 25, 2016
• First Posted (Estimate): January 28, 2016

Study Record Updates

• Last Update Posted (Actual): June 20, 2018
• Last Update Submitted That Met QC Criteria: June 19, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Keywords: Wide local excision (WLE) for breast cancer
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: LPM-007

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No